223 related articles for article (PubMed ID: 11106307)
1. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.
Liechti ME; Vollenweider FX
J Psychopharmacol; 2000; 14(3):269-74. PubMed ID: 11106307
[TBL] [Abstract][Full Text] [Related]
2. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.
Liechti ME; Baumann C; Gamma A; Vollenweider FX
Neuropsychopharmacology; 2000 May; 22(5):513-21. PubMed ID: 10731626
[TBL] [Abstract][Full Text] [Related]
3. Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.
Liechti ME; Vollenweider FX
Eur Neuropsychopharmacol; 2000 Jul; 10(4):289-95. PubMed ID: 10871712
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.
Farré M; Abanades S; Roset PN; Peiró AM; Torrens M; O'Mathúna B; Segura M; de la Torre R
J Pharmacol Exp Ther; 2007 Dec; 323(3):954-62. PubMed ID: 17890444
[TBL] [Abstract][Full Text] [Related]
5. Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin.
Liechti ME; Geyer MA; Hell D; Vollenweider FX
Neuropsychopharmacology; 2001 Mar; 24(3):240-52. PubMed ID: 11166515
[TBL] [Abstract][Full Text] [Related]
6. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.
O'Shea E; Esteban B; Camarero J; Green AR; Colado MI
Neuropharmacology; 2001; 40(1):65-74. PubMed ID: 11077072
[TBL] [Abstract][Full Text] [Related]
7. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats.
Mechan AO; Esteban B; O'Shea E; Elliott JM; Colado MI; Green AR
Br J Pharmacol; 2002 Jan; 135(1):170-80. PubMed ID: 11786492
[TBL] [Abstract][Full Text] [Related]
8. Dissociation of the neurochemical and behavioral toxicology of MDMA ('Ecstasy') by citalopram.
Piper BJ; Fraiman JB; Owens CB; Ali SF; Meyer JS
Neuropsychopharmacology; 2008 Apr; 33(5):1192-205. PubMed ID: 17609680
[TBL] [Abstract][Full Text] [Related]
9. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.
Liechti ME; Saur MR; Gamma A; Hell D; Vollenweider FX
Neuropsychopharmacology; 2000 Oct; 23(4):396-404. PubMed ID: 10989266
[TBL] [Abstract][Full Text] [Related]
10. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.
Tancer M; Johanson CE
Psychopharmacology (Berl); 2007 Jan; 189(4):565-73. PubMed ID: 17047932
[TBL] [Abstract][Full Text] [Related]
11. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.
Hysek CM; Simmler LD; Ineichen M; Grouzmann E; Hoener MC; Brenneisen R; Huwyler J; Liechti ME
Clin Pharmacol Ther; 2011 Aug; 90(2):246-55. PubMed ID: 21677639
[TBL] [Abstract][Full Text] [Related]
12. Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?
Lebsanft HB; Mayerhofer A; Kovar KA; Schmidt WJ
J Neural Transm (Vienna); 2003 Jul; 110(7):707-18. PubMed ID: 12811632
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users.
Allott K; Canny BK; Broadbear JH; Stepto NK; Murphy B; Redman J
J Psychopharmacol; 2009 Sep; 23(7):759-74. PubMed ID: 18562414
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in the subjective effects of MDMA.
Liechti ME; Gamma A; Vollenweider FX
Psychopharmacology (Berl); 2001 Mar; 154(2):161-8. PubMed ID: 11314678
[TBL] [Abstract][Full Text] [Related]
15. Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures.
Green AR; O'Shea E; Saadat KS; Elliott JM; Colado MI
Br J Pharmacol; 2005 Sep; 146(2):306-12. PubMed ID: 15997230
[TBL] [Abstract][Full Text] [Related]
16. Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.
Durkin S; Prendergast A; Harkin A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1894-901. PubMed ID: 18824064
[TBL] [Abstract][Full Text] [Related]
17. Effects of the α₂-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers.
Hysek CM; Brugger R; Simmler LD; Bruggisser M; Donzelli M; Grouzmann E; Hoener MC; Liechti ME
J Pharmacol Exp Ther; 2012 Feb; 340(2):286-94. PubMed ID: 22034656
[TBL] [Abstract][Full Text] [Related]
18. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice.
Fantegrossi WE; Godlewski T; Karabenick RL; Stephens JM; Ullrich T; Rice KC; Woods JH
Psychopharmacology (Berl); 2003 Mar; 166(3):202-11. PubMed ID: 12563544
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters.
Pifl C; Nagy G; Berényi S; Kattinger A; Reither H; Antus S
J Pharmacol Exp Ther; 2005 Jul; 314(1):346-54. PubMed ID: 15831439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
